Clinical advances in therapies targeting the interleukin-2 receptor.
نویسنده
چکیده
منابع مشابه
The Role of Interleukin (IL-22) in immune response to human diseases
Background and aims: IL-22 is an alpha- helical cytokine. IL-22 binds to a heterodimeric cell surface receptor composed of IL-10R2 and IL-22R1subunits. IL-22R is expressed on tissue cells, and it is absent on immune cells. L-22 and IL-10 receptor chains play a role in cellular targeting and signal transduction to selectively initiate and regulate immune responses. The aim of this study was to i...
متن کاملTargeting cytokines in inflammatory diseases: focus on interleukin-1-mediated autoinflammation
In this commentary, we summarize the most recent advances in the cytokine-targeting therapies. We focus on new aspects of interleukin-1 (IL-1)-mediated autoinflammation and novel strategies to target IL-1.
متن کاملInterleukin-23 Receptor Gene Variants in Acute Lymphoblastic Leukemia and Their Relation to Prognostic Factors
Background: Interleukin (IL)-23 has an important role in tumor immune regulation. Objective: To investigate the possible association of interleukin-23 receptor (IL23R) gene variants rs1884444, rs10889677 and rs11209026 with development of acute lymphoblastic leukemia (ALL). Methods: The IL23R variants were studied in 164 ALL patients and compared to 175 healthy controls by polymerase chain reac...
متن کاملImmunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
Rexinoids binding to both the retinoic acid receptor (RAR) and retinoid X receptor (RXR) families of rexinoid receptors have demonstrated clinical activity in hematologic malignancies and have been shown to mediate genes associated with both growth and differentiation. RXR rexinoids have demonstrated efficacy in the treatment of cutaneous T-cell lymphomas, but the mechanism of action is unclear...
متن کاملThe Future of Breast Cancer Treatment * —
Advances in breast cancer research have led to the development of investigational agents that demonstrate efficacy against new targets, including vascular endothelial growth factor. Likewise, new human epidermal growth factor receptor 2 antagonists are being investigated and new formulations of cytotoxic agents are being developed to improve the targeted efficacy of these agents. However, impor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- QJM : monthly journal of the Association of Physicians
دوره 96 2 شماره
صفحات -
تاریخ انتشار 2003